ArticleBioImpacts : BI2013
Inhibition of hTERT Gene Expression by Silibinin-Loaded PLGA-PEG-Fe3O4 in T47D Breast Cancer Cell Line.
Article in BioImpacts : BI, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 77 citations in OpenAlex.
- The Effects of Silibinin Combined With EGFR-TKIs in the Treatment of NSCLC.Cancer medicine · 2025Review
- Silymarin: a promising modulator of apoptosis and survival signaling in cancer.Discover oncology · 2025Review
- Biotechnological advances in microbial synthesis of gold nanoparticles: Optimizations and applications.3 Biotech · 2024Review
- Targeted delivery of silibinin via magnetic niosomal nanoparticles: potential application in treatment of colon cancer cells.Frontiers in pharmacology · 2023Article
- Fabricating niosomal-PEG nanoparticles co-loaded with metformin and silibinin for effective treatment of human lung cancer cells.Frontiers in oncology · 2023Article
- Functionalisation of FeIET nanobiotechnology · 2020Article
- Formulation Strategies for Enhancing the Bioavailability of Silymarin: The State of the Art.Molecules (Basel, Switzerland) · 2019Review
- Retraction Note to: Synthesis, characterization and in vitro studies of doxorubicin-loaded magnetic nanoparticles grafted to smart copolymers on A549 lung cancer cell line.Journal of nanobiotechnology · 2019Article
- Retraction Note: Inhibition of hTERT Gene Expression by SilibininLoaded PLGA-PEG-Fe₃O₄ in T47D Breast Cancer Cell Line.BioImpacts : BI · 2018Article
- Broad targeting of angiogenesis for cancer prevention and therapy.Seminars in cancer biology · 2015Review
- Synthesis and characterization of surface-modified Fe3O4 super-paramagnetic nanoparticles.Journal of Huazhong University of Science and Technology. Medical sciences = Hua zhong ke ji da xue xue bao. Yi xue Ying De wen ban = Huazhong keji daxue xuebao. Yixue Yingdewen ban · 2014Article
- Dendrimers: synthesis, applications, and properties.Nanoscale research letters · 2014Article
- Curcumin inhibits leptin gene expression and secretion in breast cancer cells by estrogen receptors.Cancer cell international · 2014Article
- Carbon nanotubes: properties, synthesis, purification, and medical applications.Nanoscale research letters · 2014Article
Corrections and comments
- Retraction · 2018-09-16Duplication of Data · Objections by Third Party · Unreliable Results and/or Conclusions ·
- Retracted
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction : Nowadays, using drug delivery is an essential method to improve cancer therapy through decreasing drug toxicity and increasing efficiency of treatment. Silibinin (C25H22O10), a polyphenolic flavonoid which is isolated from the milk thistle plant, has various applications in cancer therapy but it has hydrophobic structure with low water solubility and bioavailability. To increase the effect of silibinin, silibinin-loaded PLGA-PEG-Fe3O4 was prepared to determine the inhibitory effect of this nanodrug on Telomerase gene expression. Methods : The rate of silibinin loaded into PLGA-PEG-Fe3O4 was measured. Then, the cytotoxic effect of silibinin-loaded PLGA-PEG-Fe3O4 was determined by Methyl Thiazol Tetrazolium (MTT) assay. After that, inhibition of Telomerase gene expression was indicated through Real-time PCR. Results : Data analysis from MTT assay showed that silibinin-loaded PLGA-PEG-Fe3O4 had dose dependent cytotoxic effect on T47D cell line. MTT assay showed no cytotoxic effect of free PLGA-PEG-Fe3O4 on T47D breast cancer cell line. Real Time PCR analysis showed that the level of telomerase gene expression more efficiently decreased with silibinin-loaded PLGA-PEG-Fe3O4 than with free silibinin alone. Conclusion : The present study indicates that this nanodrug causes down-regulation of Telomerase gene expression in cancer cells. Therefore, PLGA-PEG-Fe3O4 could be an appropriate carrier for hydrophobic agents such as silibinin to improve their action in cancer therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.